Evidence Summary - Intermittent Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists for Asthma - NCBI Bookshelf
![PDF] Pharmacology and Therapeutics of Bronchodilators Revisited | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/166b47a25b6f4bbd20944ba231f4b7803438b1d7/5-Figure1-1.png "PDF] Pharmacology and Therapeutics of Bronchodilators Revisited | Semantic Scholar")
PDF] Pharmacology and Therapeutics of Bronchodilators Revisited | Semantic Scholar
Long-acting maintenance pharmacotherapy in chronic obstructive pulmonary disease - ScienceDirect
Proven mechanisms of action leading to synergistic or additive... | Download Scientific Diagram
Biomolecules | Free Full-Text | Pathophysiology, Therapeutic Targets, and Future Therapeutic Alternatives in COPD: Focus on the Importance of the Cholinergic System
Pharmaceuticals | Free Full-Text | Mechanisms, Pathophysiology and Currently Proposed Treatments of Chronic Obstructive Pulmonary Disease
Dual bronchodilator therapy: A review
Frontiers | Single Inhaler LABA/LAMA for COPD
Possible mechanisms of synergistic actions of the LABA/LAMA... | Download Scientific Diagram
Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy - ScienceDirect
Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium - ScienceDirect
Frontiers | Single Inhaler LABA/LAMA for COPD
Cardiac effects of current treatments of chronic obstructive pulmonary disease - The Lancet Respiratory Medicine
Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs)
Dual bronchodilation in COPD | PPT
Optimizing asthma management: Role of long-acting muscarinic antagonists - ScienceDirect
The Role of Fixed-Dose Dual Bronchodilator Therapy in Treating COPD
Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects. - Abstract - Europe PMC
Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study - The Lancet Respiratory Medicine
Frontiers | The Cholinergic Pathways in Inflammation: A Potential Pharmacotherapeutic Target for COPD
Mechanism of action of ICS. notes: when a glucocorticoid (GCS) binds to... | Download Scientific Diagram
Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management | npj Primary Care Respiratory Medicine
Comparative Effects of LAMA-LABA-ICS vs LAMA-LABA for COPD - CHEST
